Could an HIV drug tame tough reflux? new trial aims to find out

NCT ID NCT06704100

First seen Jun 24, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether a combination of fosamprenavir (an HIV medication) and sodium alginate (a seaweed-based thickener) can ease heartburn and regurgitation in people whose reflux doesn't improve with standard acid-blocking pills. Sixty adults aged 18 to 65 will take either the study drug or a placebo twice daily for 8 weeks and track their symptoms. The goal is to see if this new approach offers relief where current treatments fall short.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Fosamprenavir-Sodium Alginate (a combination of an antiviral drug and a seaweed-derived thickener)
What this could lead to
If it works, this could offer a new treatment option for people with persistent heartburn and reflux that standard acid-blocking pills don't relieve.
What could go wrong
This is a small, early-phase trial with only 60 participants, so results may not apply to everyone. The drug may prove no better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL REFLUX DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.